Paper Review Records
All Paper Review Records
15 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
In Search of Long-Term Disease Control: CAR T-Cell Therapy With Axicabtagene Ciloleucel or Allogeneic Hematopoietic Cell Transplantation Against Relapsed/Refractory Large B-Cell Lymphoma
Markus Maulhardt; Lina J. Kolloch; Gina Westhofen; Enver Aydilek; Margarete E. Laage; Christian Plate; Judith Büntzel; Alexander C. Angleitner; Kristian Thomson; Wolfram Jung; Justin Hasenkamp; Evgenii Shumilov; Gerald G. WulfShow moreShow less
Department of Hematology and Medical Oncology, University Medical Center Goettingen, Goettingen, Germany; Department of Hematology and Oncology, University Hospital Muenster, Muenster, Germany; Evangelisches Klinikum Bethel, University Hospital Bielefeld, Bielefeld, Germany; Department of Hematology, Oncology and Palliative Care, Klinikum Magdeburg, Magdeburg, GermanyShow moreShow less
Real-World Delivery, Dose Adaptation, and Molecular Monitoring of Gilteritinib, Venetoclax, and Azacitidine in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
Meiling Chen; Yuanzhong Chen; Shaoyuan Wang; Feng’e Yang; Jing Zheng; Danhui Fu; Jia Lin; Xiaofan Li; Nainong LiShow moreShow less
Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China; Translational Medicine Center on Hematology, Fujian Medical University, Fuzhou, Fujian, China; Hematopoietic Stem Cell Transplantation Center, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Department of Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian, ChinaShow moreShow less
Sequential TKI Treatment in Patients With Chronic Phase Chronic Myeloid Leukemia Resistant to Frontline Nilotinib or Dasatinib Therapy. A Real-Life Survey From the Italian Campus CML Network
Gabriele Gugliotta; Mario Annunziata; Isabella Capodanno; Davide Rapezzi; Immacolata Attolico; Marianna Caramella; Iolanda D. Vincelli; Antonella R. Rossi; Mario Tiribelli; Alessandra Malato; Michele Cimminiello; Vincenzo Accurso; Massimiliano Bonifacio; Sara Galimberti; Giuseppina Loglisci; Elisabetta Abruzzese; Monica Bocchia; Antonella Gozzini; Micaela Bergamaschi; Maria C. Miggiano; Agostino Tafuri; Grazia Sanpaolo; Anna R. Scortechini; Monica Crugnola; Debora Luzi; Luigiana Luciano; Gianni Binotto; Roberto Latagliata; Fausto Castagnetti; Alessandro Allegra; Giorgina Specchia; Uros Markovic; Gianantonio Rosti; Robin Foà; Giuseppe Saglio; Massimo Breccia; Fabio StagnoShow moreShow less
Institute of Hematology “Seràgnoli”, IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy; Hematology Unit, Cardarelli Hospital, Naples, Italy; Hematology Unit, Azienda Unità Sanitaria Locale - IRCCS, Reggio Emilia, Italy; S.C. Ematologia, Cuneo, Italy; Hematology and Stem cell Transplantation Unit, Bari, Italy; SC Hematology, Niguarda “Ca Granda” Hospital, Milan, Italy; Dipartimento Emato-Oncologia A.O.“Bianchi-Melacrino-Morelli”, Reggio Calabria, Italy; Division of Hematology and BMT, Department of Medical Area, University of Udine, Udine, Italy; UOC Oncoematologia, Palermo, Italy; Hematology and Bone Marrow Transplantation Unit, San Carlo Hospital, Potenza, Italy; UO di Ematologia, Divisione di Oncologia, AOU Policlinico “Giaccone” Università degli Studi di Palermo, Palermo, Italy; Department of Engineering for Innovation Medicine, Section of Innovation Biomedicine, Hematology Area, University of Verona, Verona, Italy; Department of Clinical and Experimental Medicine, Section of Hematology, University of Pisa, Pisa, Italy; Hematology Unit, “Vito Fazzi” Hospital, Lecce, Italy; Hematology Department, “S. Eugenio” Hospital, Tor Vergata University, Rome, Italy; Hematology Unit, University of Siena, Siena, Italy; Hematology Unit, AOU Careggi, University of Florence, Florence, Italy; IRCCS Ospedale Policlinico S. Martino, Dipartimento di Oncologia ed Ematologia, Dipartimento di Oncologia, S.S.D Malattie del Sangue e Neoplasie Degli Organi Emolinfopoietici, Genova, Italy; Hematology Department, San Bortolo Hospital, Vicenza, Italy; Hematology Unit, University Hospital Sant'Andrea-Sapienza, Rome, Italy; Division of Hematology, Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy; Hematology Unit, Azienda Ospedaliero Universitaria Ospedali Riuniti, Ancona, Italy; Hematology Unit, University Hospital of Parma, Parma, Italy; Onco-Hematology Department, AO Santa Maria, Terni, Italy; Division of Hematology and Bone Marrow Transplantation, University of Naples Federico II, Naples, Italy; Department of Medicine, Hematology and Clinical Immunology, Padua School of Medicine, Padua, Italy; Hematology Unit, Viterbo, Italy; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; Hematology Section, AOU Policlinico “G. Martino”, University of Messina, Messina, Italy; Division of Hematology, A.O.U. “Policlinico-San Marco”, University of Catania, Catania, Italy; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy; Hematology, Department of Translational and Precision medicine, Sapienza University of Rome, Rome, Italy; Divisione Universitaria di Ematologia e Terapie Cellulari, Torino, ItalyShow moreShow less
Immunoglobulin D-Associated AL Amyloidosis: Clinical Features and Outcomes
Sarika D. Gurnani; Andrew Staron; Lisa M. Mendelson; Natasha J. Burke; Vaishali SanchorawalaShow moreShow less
Amyloidosis Center, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MAShow moreShow less
Safe Integration of Radiation Therapy With Bispecific Antibodies in Relapsed/Refractory B-cell Lymphomas
Jonathan A. Baron; Monica Chelius; Gurbani Singh; Michael D. Schad; Melanie Berger; Emeline R. Chong; Colin J. Thomas; Jordan S. Carter; Michael R. Cook; Sunita D. Nasta; Daniel J. Landsburg; Stefan K. Barta; Jakub Svoboda; Stephen J. Schuster; Nikhil Yegya-Raman; Michael J. LaRiviere; John P. Plastaras; Elise A. Chong; Harper HubbelingShow moreShow less
Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA; Division of Hematology and Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PAShow moreShow less
Clonal Hematopoiesis in Newly Diagnosed Multiple Myeloma: Associations With Neutropenia, Supportive Care Burden, and Survival
Ahmet Yigitbasi; Fulya Oz Puyan; Hakki Onur Kirkizlar; Tugcan Alp Kirkizlar; Nuray Can; Ebru Tastekin; Seyma Keles Karahan; Elif Gulsum Umit; Ahmet Muzaffer DemirShow moreShow less
Department of Hematology, Faculty of Medicine, Trakya University, Edirne, Türkiye; Department of Pathology, Faculty of Medicine, Trakya University, Edirne, Türkiye; Department of Internal Medicine, Faculty of Medicine, Trakya University, Edirne, TürkiyeShow moreShow less
FAQ
How long does Clinical Lymphoma Myeloma & Leukemia take to review a manuscript?
As of 2026-11-14, CrushSCI has 15 complete review records for Clinical Lymphoma Myeloma & Leukemia. The fastest paper went from submission to acceptance in 12 days (Knowledge, Awareness, and Practice Patterns of Nephrologists in the Diagnosis and Management of Multiple Myeloma (MIND-MM Study): A Cross-Sectional, Web-Based, CHERRIES-Compliant Survey with Position Statement from the Indian Myeloma Academic Groupe (IMAGe) and Indian Society of Nephrology (ISN), received 2026-05-31, accepted 2026-06-12); the slowest took 99 days. The average is 42.4 days and the median is 41 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
